How to Obtain Evidence in the U.S. for International Dispute Resolution

Let’s say you have a lawsuit or an arbitration in Ireland or Northern Ireland and need to obtain evidence in the U.S. How do you do it?

My partner Gene Burd has written an article, recently published on the Young Arbitration Review, on the use of ‘1782’ actions in connection with international arbitrations. 1782 refers to the section of the United States Code that provides a process to obtain evidence in the U.S. for litigation/arbitration outside the U.S. Although Gene’s article focuses on 1782 actions in the arbitration context, the article provides valid insights for litigation.  The article can be found here. Feel free to contact Gene (or me) if you have any questions.

What Irish and Northern Irish Companies Need to Know Now: Doing Business in the U.S.–Free Webinar

Irish Export Insights

Thursday, June 30, 2016 at 3:00 pm Dublin/Belfast.

The attorneys of Arnall Golden Gregory’s International Business Practice invite you to attend a complimentary, 60-minute webinar “What Irish and Northern Irish Companies Need to Know Now: Doing Business in the U.S.” The webinar will be held Thursday, June 30, 2016 at 10:00 am EDT (3:00 pm Dublin/Belfast). The United States is an attractive, and expanding, market for Irish and Northern Irish goods and services. Despite suggestions to the contrary, the U.S. can be an easy market for business expansion—with a little bit of planning. This webinar will examine key legal issues for doing business in the U.S., including:

  • Protecting the Irish and Northern Irish parent company, its investors, and capital from U.S. legal risk;
  • Avoiding branch profits tax issues;
  • Reducing payment risk by ensuring prompt payment from customers, and other U.S. contract essentials;
  • The product liability risks that may attach…

View original post 127 more words

Expert Webinar on FDA Off-Label Communications Regulations

The US FDA’s regulation of ‘off-label communications’ (communications about the use of FDA-approved pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration) can be complex and confusing, especially for Irish and Northern Irish life sciences companies marketing/distributing their product in the US. Recent FDA actions have muddied the waters a bit more. Without clear guidance from the FDA , life sciences companies are struggling to decide how best to approach off-label communications, if at all. Continue reading

Critical Changes to US Visa Waiver Program Impact Irish/NI Companies

Bottom line up front: as of last Friday, new changes to the US’s Visa Waiver program restrict the use of that program by persons who have visited Iran, Iraq, Syria, or the Sudan at any time after March 1, 2011. Additional “countries of concern” may be added to this list. The nationality of the traveler is not an issue, so this change impacts any person traveling on an Irish or UK passport who has been to the listed countries in the relevant timeframe. Continue reading

Free Webinar on Background Screening of Employees and Applicants

Recently, a client (a Northern Irish company) asked me about what they could and could not do when interviewing and screening potential employees, including the extent to which the company could perform a formal background screen on each applicant.  Luckily–for everyone involved–one of my partners is an expert in this area.

Continue reading

Some Considerations for Non-U.S. Companies on U.S. Civil Litigation

Civil litigation in the U.S. can be an adventure for non-U.S. companies–we are after all, a common law country (not a difference from Ireland or Northern Ireland). Here are some points for Irish/NI companies to keep in mind: Continue reading